The Vanguard Group 13D and 13G filings for Atossa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-29 11:26 am Sale | 2025-06-30 | 13G | Atossa Therapeutics, Inc. ATOS | The Vanguard Group | 5,833,127 4.510% | -765,169 (-11.60%) | Filing |
| 2024-11-12 1:32 pm Unchanged | 2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS | The Vanguard Group | 6,598,296 5.240% | 0 (Unchanged) | Filing |
| 2024-11-04 11:27 am Purchase | 2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS | The Vanguard Group | 6,598,296 5.240% | 900,760 (+15.81%) | Filing |
| 2023-02-09 11:07 am Sale | 2022-12-30 | 13G | Atossa Therapeutics, Inc. ATOS | The Vanguard Group | 5,697,536 4.500% | -1,273,314 (-18.27%) | Filing |
| 2022-02-09 3:24 pm Purchase | 2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS | The Vanguard Group | 6,970,850 5.510% | 6,970,850 (New Position) | Filing |